best practice:- Issue 8 Contents

Article is 2.5 years old

Search by:

Issue 8 September 2007 - Contents

Welcome to Issue 8

Gout - Hit the target
Carvedilol: Is it superior to metoprolol in heart failure?
Prexige: Lumiracoxib linked to deaths in Australia
Co-Emzyme Q10: Would you like fries with that?

Gout	Select
Summary points What is gout Treatment of gout Indications for Uric acid lowering therapy Lifestyle interventions Pharmacists have a key role in the care of people with gout Prevalence and impact of gout References
A Slow death from colchicine	Select
Contributed by Safe and Quality Use of Medicines
Is carvedilol superior to metoprolol in heart failure?	Select
Carvedilol may be an option for patients initiating beta-blocker treatment for heart failure or patients in whom metoprolol is poorly tolerated. We present the results of the COMET trial and other research and discuss strategies for initiating carvedilol treatment.
Lumiracoxib linked to deaths in Australia	Select
Medsafe have just announced that approval for lumiracoxib (Prexige) 400 mg tablets has been revoked in New Zealand. This follows the news that lumiracoxib has been completely withdrawn in Australia after it emerged that the drug was linked to serious adverse reactions including liver failure and death.
Essentials	Select
Upfront: The role of co-enzyme Q10 supplements in medical treatment Ten Minute Audit: Identifying patients on colchicine Dear Dave: Does the ‘seven day rule’ still apply with the concomitant use of combined oral contraceptives and all antibiotics? Serotonin toxicity: “Is combining Reductil with tricyclic antidepressants really such a no-no or are the drug companies just being defensive over the unlikely occurrence of serotonin syndrome?” Correspondence


About us	Contact us	Home

© bpac^nz 2009